A new mRNA flu vaccine made by Moderna was approved by the FDA in August, and is currently available for people aged 50 and over. The promise of an mRNA vaccine for flu is that it can be spun up more quickly than a traditional vaccine, meaning it could better match the flu strain that’s circulating.

Is that what happened this year? How are the side effects? And how has dysfunction at the health agencies impacted rollout? Flora discusses these questions and more with vaccine researcher Anna Durbin.

Guest:

Dr. Anna Durbin is a vaccine researcher, professor of international health, and director of the Center for Immunization Research at the Johns Hopkins Bloomberg School of Public Health.

Transcripts for each episode are available within 1-3 days at sciencefriday.com.

Subscribe to this podcast. Follow our show on Instagram, TikTok, Facebook, and Bluesky @scifri and sign up for our newsletters. Got a science question that’s keeping you up at night? Call us: 877-472-4374

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

The science and politics of the new mRNA flu vaccine

Science Friday

The science and politics of the new mRNA flu vaccine